Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Psychiatry Reports|March 20, 2001
Neuroimaging in Alzheimer's disease: relevance for treatmentC H van Dyck
Archives of General Psychiatry|February 9, 2000
Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study GroupC H van Dyck, P Newhouse, W E Falk, et al.
Neurobiology of Aging|January 1, 1997
The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeysA F Arnsten, C H Lin, C H Van Dyck, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 16, 2000
The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory taskR A Avery, J S Franowicz, C Studholme, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 3, 2001
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humansD Martinez, J Gelernter, A Abi-Dargham, et al.
Neurology|November 19, 2008
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trialJ J Sevigny, J M Ryan, C H van Dyck, et al.
Annals of Internal Medicine|December 15, 1990
Clarifying confusion: the confusion assessment method. A new method for detection of deliriumS K Inouye, C H van Dyck, C A Alessi, et al.
Neurology|July 29, 2011
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseM Sano, K L Bell, D Galasko, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 23, 1998
Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patientsJ P Seibyl, K Marek, K Sheff, et al.
The Journal of Prevention of Alzheimer'S Disease|October 24, 2023
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's DiseaseS Cohen, C H van Dyck, M Gee, et al.
Pageof 5